Morphine Sulfate Extended-Release Tablets 15 mg, 100-count per bottle, Rx Only, Manufactured by Mayne Pharma, Greenville, NC 27834, NDC 51862-185-01.
Dr. Reddy's Laboratories
Failed Impurities/Degradation Specification
💊 Drugs • 11,927 recalls
Dr. Reddy's Laboratories
Failed Impurities/Degradation Specification
Labeling: Missing Label
Staska Pharmaceuticals
Presence of Particulate Matter: Presence of glass particulates.
Dr. Reddy's Laboratories
Failed Impurities/Degradation Specification
BLI International
Superpotent Drug: Stability failure for assay at 6 months test time-point.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Dr. Reddy's Laboratories
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Dr. Reddy's Laboratories
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Dr. Reddy's Laboratories
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations
C & A Naturistics
Marketed without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared diclofenac and acetaminophen.
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations
Fresenius Kabi Compounding
cGMP violations